Head-To-Head Analysis: enGene (NASDAQ:ENGN) versus iTeos Therapeutics (NASDAQ:ITOS)

iTeos Therapeutics (NASDAQ:ITOS) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Volatility and Risk

iTeos Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, enGene has a beta of -0.65, meaning that its stock price is 165% less volatile than the S&P 500.

Valuation and Earnings

This table compares iTeos Therapeutics and enGene”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iTeos Therapeutics	$12.60 million	21.48	-$112.64 million	($3.15)	-2.35
enGene	N/A	N/A	-$55.14 million	($0.58)	-10.76

enGene has lower revenue, but higher earnings than iTeos Therapeutics. enGene is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by insiders. Comparatively, 13.7% of enGene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for iTeos Therapeutics and enGene, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iTeos Therapeutics	0	0	4	0	3.00
enGene	0	1	8	1	3.00

iTeos Therapeutics presently has a consensus target price of $22.25, suggesting a potential upside of 200.27%. enGene has a consensus target price of $25.89, suggesting a potential upside of 314.69%. Given enGene’s higher probable upside, analysts clearly believe enGene is more favorable than iTeos Therapeutics.

Profitability

This table compares iTeos Therapeutics and enGene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iTeos Therapeutics	N/A	-20.11%	-17.50%
enGene	N/A	-16.69%	-14.27%

Summary

enGene beats iTeos Therapeutics on 8 of the 12 factors compared between the two stocks.

About iTeos Therapeutics

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.